Alexander Spira, MD, PhD, FACP

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Lilly
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Black Diamond Therapeutics
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Sanofi
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Array BioPharma
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    AstraZeneca/MedImmune
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Bristol-Myers Squibb
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Blueprint Medicines
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    LAM Therapeutics
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Roche
    Date added:
    08/16/2023
    Date updated:
    08/16/2023
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    AstraZeneca
    Date added:
    08/16/2023
    Date updated:
    08/16/2023

Pages

Return to 2023 Annual Symposium For Evolving Therapies and Drug Development in Oncology: Targeted therapy, immunotherapy and beyond